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Abstract
The purpose of this study was to clarify the biological behaviour of branch duct type intraductal papillary mucinous
neoplasm (IPMN) by evaluating serial changes at magnetic resonance cholangiopancreatography (MRCP). Fifty-two
patients with a diagnosis of branch duct IPMN based on either endoscopic retrograde cholangiopancreatography
(ERCP) (9/52) and/or MRCP examination (43/52), were followed up over a mean period of 31.2 months
(range 12!108). All imaging data were retrospectively reviewed by two radiologists in order to evaluate serial changes
in the maximum diameter of the cystic lesion, in the presence of main pancreatic duct dilatation (MPD), and filling
defects within the lesion. Statistical analysis was performed using the Fisher exact probability test. Serial MRCP
proved growth in seven cases. In two cases the size decreased; in the remaining 43 there was no change in size.
Lesions greater than 3 cm at presentation and the presence of MPD dilatation or filling defects at imaging were
most likely to grow. Only 2/37 cystic lesions less than 3 cm in diameter grew in size over the period of observation.
No cystic lesion showed changes in morphology and structure. Branch duct IPMNs smaller than 3 cm, without
associated filling defects, tend to be stable, making "watch and wait# management possible.
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Introduction
The intraductal papillary mucinous neoplasm (IPMN) of
the pancreas was first described in the 1980s; its actual
classification among cystic lesions of the exocrine pan-
creas was established in 1996[1,2]. With the improvement
of techniques and modalities of cross sectional imaging
studies, the detection of this lesion continues to increase
and has become a topic of growing scientific interest[3!8].
IPMN arises from the epithelium of the pancreatic
ductal system and can display the full spectrum of
histologic dysplasia, including hyperplasia, adenoma,
borderline tumour, in situ or invasive carcinoma. The
hypothesis of a temporal sequence of progressive adeno-
ma!carcinoma degeneration is generally accepted[9].
Three morphologic types of lesions are recognized
based on their location within the duct system: lesions
exclusively of the main duct, lesions restricted to the
branch ducts, and those in both main duct and branch
duct (combined). Radiological features strongly corre-
lated with a given lesion#s malignant potential include:
size43 cm, mural irregularity or nodules, and dilation
of the main pancreatic duct (MPD)[4]. When involve-
ment is limited to the branch ducts (BD-IPMN), the
lesion is more often benign, non-symptomatic and slow
growing[5,10,11].
There is considerable controversy regarding the treat-
ment of these lesions. Some centres advocate surgical
resection for most lesions, whereas others favour serial
follow-up[12!15], especially in cases with normal clinical
laboratory analyses and minimal radiological findings,
or in patients with significant comorbidities[16,17].
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As a result of the non-uniform approach to these lesions,
there are few available studies analysing significant num-
bers of patients undergoing long term follow-up[6!8,17].
The aim of this study is to analyse retrospectively serial
changes in the imaging history of branch duct type
IPMN as depicted by magnetic resonance cholangiopan-
creatography (MRCP) in a series of patients in whom




The study was approved by our institutional review
board. In our hospital, according to the international
guidelines for the management of BD-IPMN[6] patients
were considered candidates for follow-up based on either
(a) imaging criteria: largest diameter of the mass less
than 35mm; absence of papillary proliferations, calibre
of MPD less than 5mm and (b) clinical criteria: no
abdominal symptoms, no evidence of diabetes, no labo-
ratory evidence of biliary obstruction and normal tumour
markers. The decision to manage BD-IPMN conserva-
tively required patient#s consent.
Fifty-two consecutive patients (22 males and 30
females, average age at initial examination 64.2 years,
range 43!79 years) in whom an imaging diagnosis
of BD-IPMN was made between January 1997 and
December 2005 were selected from the database of our
Radiology Department. The diagnosis was established by
MRCP in 43/52 (82.7%) and corroborated by endo-
scopic retrograde cholangiopancreatography (ERCP) in
9/52 (17.3%). MRCP was considered diagnostic when a
cystic pancreatic mass communicating with the main
pancreatic duct (MPD) through a small channel was
identified. All patients were followed every 6 months
for a period of time greater than 12 months. The average
time of follow-up was 31.2 months (range 12!108
months).
The number of follow-up examinations per patient
varied from 1 to 6 with an average of 2.9. The total
number of magnetic resonance (MR) examinations was
152. Only two patients underwent surgery during the
follow-up period.
In order to avoid inclusion errors patients with previ-
ous episodes of acute pancreatitis in whom there was no
ERCP corroboration of BD-IPMN were not considered;
those with any dilatation of the MPD greater than 5mm;
and those followed up by methods other than MRCP, or
those with less than 1 year total follow-up were also
excluded. Patients unwilling to sign the consent form
were also excluded.
MRCP imaging technique
The MR examinations were performed on a 1.5-T MR
imaging system (Magnetom Symphony and Maestro;
Siemens Medical Systems, Erlangen, Germany) using a
body phased-array coil. Twenty minutes prior to the
examination, the patients were given 150ml of an oral
superparamagnetic contrast medium (Lumirem",
Guerbet-France) to minimize the high signal originating
in the stomach and duodenum. All the sequences, except
for 3D MRCP, were carried out in breath-hold.
Two types of MRCP sequences were utilized in each
patient: (a) half-Fourier single-shot turbo spin-echo
(HASTE), multi-slice, and (b) RARE 60mm "thick
slab# projection views of the bilio-pancreatic tree were
obtained in each patient. The HASTE sequence (recovery
time (TR) 800ms, echo time (TE) 60ms, field of
view 350" 300, matrix 240" 256) was carried out on
26 slices with a thickness of 4mm (no gap) in the axial,
coronal, para-coronal oblique and sagittal planes for
an acquisition time (TA) of 24 s. The "thick slab#
(TE 1100ms) was obtained in the coronal plane with
variable angulations and in the axial plane to optimise
the view of the pancreatic duct system. In 10 patients we
also utilized a 3D T2-weighted turbo spin echo sequence
(TR 1820, TE 272ms, field of view 350" 300, matrix
240" 256, partition thickness 1.5mm) with respiratory
triggering (TA 3min). The entire pancreatic examination
also included enhanced images (0.2ml/kg of gadolinium-
DOTA, Dotarem", Guerbet, France) of the upper
abdomen using initially only a fat suppressed (FS)
T1-weighted 2D gradient recalled echo (GRE) sequence
and since the beginning of 1999 a 3D breath-hold
sequence (volumetric interpolated breath-hold examina-
tion (VIBE) with less than 2mm voxel size, partitions
thickness 1.5mm, matrix 256" 240, TA 24 s), during
both pancreatic and portal phases of enhancement.
Image analysis
One hundred and fifty-two MR exams from the
52 patients were reviewed retrospectively by two expert
radiologists (more than 4 years training on body MR);
consensus was obtained in case of discrepancies. For the
purpose of this study MRCP and post-contrast
T1-weighted images were analysed. The following para-
meters were evaluated: multiplicity, location, size, wall
thickness, presence or absence of filling defects (called
also papillary proliferations or nodules), widest diameter
of MPD. We considered the following features "suspi-
cious imaging elements#, reported in the literature to indi-
cate high risk of malignancy: size, filling defect, dilation
of MPD and thick wall. The presence of a communicat-
ing duct between cystic lesions and MPD was also
assessed.
The greatest diameter of the lesion in the specific plane
that displayed the greatest diameter was recorded using
electronic callipers. This plane of measurement was kept
constant for all subsequent follow-up examinations.
The eventual presence of imaging changes during
serial follow-up was checked for all cystic lesions. Both
absolute measurement as well as percentage change were
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recorded. In an attempt to avoid errors associated with
measuring small lesions, we agreed arbitrarily to consider
any change greater than 20% as significant.
The wall was analysed in both HASTE and T1 post-
contrast sequences considering "thickened# when it mea-
sured41mm along any portion of the circumference of
the lesion. Filling defects were defined as nodular or
papillary projections in the wall of the cystic lesion that
displayed enhancement following gadolinium injection.
The widest diameter of the MPD was measured
with electronic callipers. According to the literature, the
following criteria indicate suspicious imaging elements:
largest diameter430mm, papillary proliferations, thick
walls, MPD size greater than 5mm.
The initial MRCP findings and any eventual changes
were analysed statistically using the Fisher exact proba-
bility test (p50.001 was considered statistically signifi-
cant). The following changes in the imaging aspects were
analysed: cystic lesion and MPD size, aspect of the wall
(papillary proliferations and thickness). Any correlation
between the presence of suspicious imaging elements and
changes in the imaging history during follow-up were
investigated.
Results
A total of 119 lesions were detected, however the largest
in each patient (n¼ 52) was analysed. In 15/52 (28.8%)
patients, the IPMNs were solitary; 37/52 (71.2%) patients
had multiple lesions. In 20/52 (38.6%) patients the lar-
gest lesion was located in the head or in the uncinate
process of the pancreas, in 15/52 (28.8%) in the isthmus
(also referred to as the neck), in 15/52 (28.8%) in the
body and in 2/52 (3.8%) in the tail. In 12/37 (32.4%)
patients with multiple tumours, all the pancreatic seg-
ments were involved; in 25/37 (67.6%), the neoplasms
were located in the head and tail of the gland, sparing the
body (Fig. 1). The largest diameters of the lesions at the
initial examination varied between 7 and 35mm (average
17.0mm; median size 15.0mm); 6 lesions measured
between 5 and 9mm, 30 lesions measured between
10 and 19mm, 9 measured between 20 and 30mm,
and 7 more than 30mm. The maximum size of the
main duct was between 2 and 5mm (average 2.8mm)
at the first examination.
In 15/52 (28.8%) of the patients, excluded from sur-
gery because of elderly age or affected by comorbidities,
at least one of the previously mentioned suspicious ima-
ging elements was present at the time of diagnosis
(Table 1). The largest cystic lesion in 5/15 (33%) was
430mm maximum diameter; 11/15 (73.3%) had papil-
lary proliferations measuring $5mm in largest dimen-
sion; in 2/15 (1.3%) of the patients the MPD was
greater than or equal to 5mm (5mm in both cases).
None of the lesions had walls 41mm in thickness.
In 37/52 (71.2%) of the patients, there were no suspi-
cious imaging elements at diagnosis.
A B
Figure 1 A 46-year-old woman with multifocal BD-IPMN. 3D MRCP sequences in the coronal (a) and axial
(b) projections show multiple cystic lesions in communication with the MPD, the greatest in the head of the pancreas
(arrows). The patient did not show any change in morphology and size of the lesions after a follow-up period of 3 years.
Table 1 Correlation of follow-up findings in patients with suspicious imaging findings (N¼ 15 patients)
No change Decrease lesion size Increase lesion size Nodule change Increase in MPD Total
43 cm 0 1 2 0 0 3
Papillary proliferations 7 0 1 0 0 8
Wide MPD 0 0 0 0 1 1
43 cm and nodules 0 0 1 0 1 2
Wide MPD and nodules 0 0 1 0 0 1
Total 7 1 5 0 2 15
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Significant changes were observed in 11/52 (21%)
patients (Table 2). Seven of the patients in whom serial
changes were observed were from the group of 15
patients with "suspicious findings# at initial imaging
(46.7%); 4 of the lesions increased in maximum diameter
(Fig. 2); 1 lesion decreased (Fig 3), 1 showed an increase
in the diameter of the MPD, one showed increasing size
of the lesion and the MPD. Four of the patients in whom
serial changes were observed were from the group of
37 patients with no "suspicious findings# at the initial
imaging study (10.8%). Lesions increased in size in
2 patients, decreased in size in 1 patient (Table 2).
The MPD increased in size in the remaining patient.
Two out of 6 patients who demonstrated more than
20% increase in size of the cystic lesion were sent to
surgery. The final pathological proof diagnosis was ade-
noma and borderline tumour.
The MPD was normal and remained unchanged in
49/52 (94.2%) patients (Fig. 4). The widest diameter
was %5mm in 3/52 (5.8%). In 1/3 of these patients,
it increased from 5 to 6mm in the tail level over a
period of 22 months; in 1 it grew from 2 to 5mm at
the pancreatic head after 42 months; in 1, there was a
diffuse increase in diameter of the MPD from 4 to 5mm
after a follow-up of 46 months (Table 2).
None of the cases showed changes in the papillary
proliferations or in other morphologic aspects of the
masses.
Thirteen patients, whose MRCP was done at the begin-
ning of our experience, underwent an ERCP to corrobo-
rate the diagnosis obtained with MRCP. The results
were positive for IPMN in 9 (69.2%) and negative in
4 (30.8%). Four of 9 patients in which the ERCP diag-
nosed IPMN had lesions localized at the head or at the
uncinate process, and 5/9 were multifocal. All patients in
which the ERCP was not diagnostic for IPMN had cystic
masses in the pancreatic tail and at the body; in these
A B
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Figure 2 A 61-year-old woman with increase in size of a BD-IPMN. Axial and coronal HASTE sequences (a,b) show
a cystic lesion of the head of the pancreas larger than 30mm communicating with the MPD. The mass had significantly
increased in size over 52 months follow-up (c,d).
Table 2 Comparison of follow-up observations in those
patients with or without suspicious elements (lesion43cm,





No change 33 8
Increase in lesion size 2 5
Decrease in lesion size 1 1
Enlarging papillary proliferations 0 0
Increasing size of MPD 1 1a
Total 37 15
aOne patient showed increasing size of the lesion and of the MPD.
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cases the low pressure of the contrast medium injection
failed to demonstrate the communication between the
cystic lesion and MPD.
The 52 patients were then subdivided into two groups
based on the duration of the follow-up (Table 3). In those
with a total follow-up period of less than 36 months
(N¼ 38), 25/38 (65.8%) of the patients presented only
with the cystic mass; in 13/38 (34.2%), at least one
additional related imaging abnormality was present: max-
imum diameter430mm (3/13 patients), papillary prolif-
erations (8/13 patients), MPD %5mm (1/13 patients),
nodules and significantly dilated MPD (1/13 patients).
In the group with a total follow-up period of more than
36 months (N¼ 14 patients), 12/14 (85.7%) presented
only with the mass at initial imaging, and in 2/14
(14.2%), at least one element was present: maximum
diameter 430mm in 1 and papillary proliferations in
the other.
Comparing those patients in whom the lesions
changed size with those with stable lesions, we
found a statistically significant association between
those lesions 43 cm diameter and increasing size
(p¼ 0.0139) (Table 4). Neither nodules nor MPD size
alone have association with increase in size (p¼ 0.0164)
(Table 4). The presence of nodules was not significantly
associated with the lesion#s size increase (p¼ 0.1542),
neither was follow-up length or main duct dilation
(Table 4).
Discussion
The increasing recognition of BD-IPMN in daily clinical
practice is directly related to the widespread use of cross-
sectional imaging and advances in technology.
In attempting to establish the diagnosis, high quality
MRCP is considered the gold standard study for these
patients[18,19], although Sahani et al. showed that MDCT
combined with 2D curved reformation can detect the BD-
IPMN and establish communication with MPD, that are
almost equivalent to those provided at MRCP[20].
The diagnosis is established by demonstrating that the
cystic pancreatic mass communicates with the MPD.
This communication can usually be confirmed on 2D
images, but can be visualized in almost every case
using current 3D T2 turbo spin echo (TSE) acquisition
with respiratory trigger[3!21]. Additionally, current mag-
netic resonance imaging (MRI) technology can precisely
depict significant morphologic and architectural features
of the lesion, such as papillary proliferations, septations
and nodules. MRCP is optimal for long term follow-up
because of the absence of radiation and the ability to
show minimal small changes[11,22]. MDCT will often be
A B
C D
Figure 3 A 46-year-old man with decrease in size of a BD-IPMN. Initial MR examination (MRCP and axial HASTE)
(a,b) showed a bilobed cystic lesion in the body of the pancreas close to the MPD (arrows). The lesion had decreased in
size 45 months later (c,d) (curved arrows).
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the test where the lesion is initially detected and commu-
nication suggested. However, because of radiation con-
siderations, we suggest that subsequent examinations be
performed with MRI. ERCP may be useful in those cases
where the presence or absence of communication is
unclear. However, ERCP is limited because thick
mucin may fill the side branch duct and prevent the con-
trast filling the mass. Sampling of pancreatic secretion at
ERCP is diagnostic only in 30% of cases[23]. Some
authors report the utility of endoscopic ultrasonography
(EUS), with or without fine needle aspiration as the first
modality of study of any pancreatic cystic lesion.
However, EUS is invasive, operator-dependent, not
always easily accessible; we also have to consider that
small lesions cannot be easily biopsied[24], and false pos-
itive results are possible in asymptomatic high-risk
patients[25]. For these reasons MRCP seems to be the
new gold standard imaging modality for this kind of dis-
ease making it quite easy to differentiate BD-IPMN from,
for example, serous cystadenoma, that do not communi-
cate with MPD.
BD-IPMNs have been described as malignant in only
approximately 20% of cases[6,10,26!28]. Nakagohri et al.
reported that BD-IPMNs having a maximum diameter of
2.5 cm tend to be less aggressive and have a better
long-term survival compared to main duct-IPMNs[10].
In a series of 13 patients with BD-IPMN, Terris et al.
reported no cases of invasive carcinoma[16].
The lesions are frequently multiple (71% in our series)
and of these, 23% had lesions throughout the entire gland
therefore a total pancreatectomy would be necessary for
complete therapy. The clinician is left with the difficult




Figure 4 A 59-year-old man with a stable BD-IPMN. Initial MR examination (MRCP and axial HASTE sequences)
showed a small cystic mass in the head of the pancreas (a,b) (arrowhead in b). MRCP clearly depicted a
small communicating duct (arrow). Axial HASTE showed a fluid!fluid level due to mucin within the cystic
lesion (b). Subsequent MRCP examinations (c) demonstrated no change in size over a 45-month follow-up period of
observation (c).
Table 3 Correlation between duration of follow-up and










436 14 1 13 n.s.
536 38 6 32
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BD-IPMN are initially detected by imaging, those fea-
tures that identify a given mass as having a higher likeli-
hood of growth and or malignancy must be carefully
investigated. The radiologist must be sure that any ima-
ging procedure is performed with proper technique such
that those features predictive of malignancy are clearly
delineated[6].
In our study, 15 of the 52 patients displayed suspicious
imaging features (430mm, papillary proliferations, MPD
calibre %5mm); 7 of these lesions grew, whereas only 2
lesions in the 37 patients without additional suspicious
imaging features displayed serial growth.
The most significant imaging feature predicting which
lesions would grow was the size of the lesion (%3 cm in
widest dimension) at the initial imaging examination. The
presence of any combination of suspicious findings was
predictive of growth when compared with lesions that
were bland cysts (Table 4). These results have been
observed by others highlighting the importance of size
in the characterization of a malignant or at least suspi-
cious IPMN[5,6].
As to the relationship between papillary proliferations
and growth, as present in 11/52 patients, we never
observed any change in the size or number of papillary
proliferations; furthermore, all the papillary proliferations
smaller than 3mm in diameter remained stable. It is pos-
sible that since we excluded BD-IPMN with papillary
proliferations larger than 5mm in the follow-up protocol,
the mural changes had poor correlation with further
growth. The fact that the MPD was less than 6mm in
all cases can explain the absence of correlation with the
change in the size of the lesions.
The size of MPD increased in 3/52 patients. None of
these patients was operated on due to compromised clin-
ical status but according to the literature these patients
should be sent to surgery[6,17,21].
In 7/52 (13.5%) patients, an increase in size of the
lesion (range 24!46.7%, mean increase 31.6%, median
follow-up 27.1 months) was demonstrated. The greatest
increase in our series was 46% in almost 2 years.
Although increase in tumour size does not necessarily
indicate malignancy, growth of a clearly diagnosed
branch duct IPMN remains an absolute indication for
surgical intervention. Despite this, as shown from our
data, the vast majority of BD-IPMN (especially those
with no suspicious imaging features) will not grow over
a long period of observation. It should be remembered
that growth does not necessarily indicate neoplastic trans-
formation. Obstruction of a communicating side branch
can result in a build up of mucin resulting in increasing
size of the lesion.
Two of the 6 patients in whom an increase in size of
the tumour was observed underwent surgery. In both
cases, the final histological diagnosis was adenoma and
borderline carcinoma. The remaining 4 patients did not
undergo surgery because of advanced age and associated
comorbidities.
Two of the IPMNs actually decreased in size. This
observation has also been reported by Irie et al.[27] in
IPMN, but is unusual in cystic neoplasms that are not
IPMN. We believe that the decrease in size is explained
by either changes in the blood supply, decreased mucin
production, or emptying of the mucin into the MPD. For
the same reason it is possible to observe minimal increase
in the diameter of the MPD that may not always mean
neoplastic transformation[26!28].
Our results suggest that patients with BD-IPMN43 cm
in largest dimension, papillary proliferations and a
dilated MPD, have a lesion with a greater likelihood
of growth (Table 4). In patients without any suspicious
feature (37/52), during a mean follow-up period of
31.2 months, we observed a significant change in only
2/37 cases (5.4%).
Total absence of suspicious features does not mean
that the lesion can be ignored. A recent consensus meet-
ing on the management of intraductal papillary mucinous
tumours of the pancreas suggested for BD-IPMNs that
"until definitive studies are performed, yearly follow-up if
Table 4 Comparison of lesions that grew against those that did not grow
Initial MRCP findings No. of patients Increase in size No increase in size Significance
Suspicious elements
Yes 15 5 10 0.0164
No 37 2 35
Max diameter (mm)
430 5 3 2 0.0139
$30 47 4 43
Main duct dilation
Yes 2 1 1 n.s.
No 50 6 44
Papillary proliferation
Yes 11 3 8 0.1542
No 41 4 37
There was a statistically significant independent association between lesions43 cm at initial imaging and subsequent increase in the size of the
lesion and between the general presence of suspicious imaging findings and growth. No significant correlation between the presence of nodules
alone, or the MPD diameter and lesion growth could be obtained.
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lesion is510mm in size, 6!12 monthly follow-up for
lesions between 10 and 20mm, and 3!6 monthly
follow-up for lesions420!30mm is advised#[6]. In our
protocol, we chose to follow all patients at 6 month
intervals for the first 2 years and 1 year intervals there-
after. The criteria and timing of the follow-up protocol
adopted in our institution seems to be reasonably sensi-
tive to detect significant growth. In fact, after a mean
follow-up of 31.2 months all the patients were alive and
none showed signs of malignancy or symptoms.
Because of the potential malignancy of the IPMNs
long term follow-up is recommended for all patients.
The interval of follow-up can be lengthened to every
year after 2 years of no change[6].
The main limitations of this study are: retrospective
nature; diagnosis based exclusively on imaging findings
at MRCP in 82.7%; examination intervals were different
in frequency and time for every patient; a mean follow-up
time of 31.2 months may still be too short to judge the
stability or growth rate of BD-IPMN; we checked only the
biggest lesions at follow-up even in cases of multifocal
IPMNs. Finally, surgical correlation is present in only
2 patients.
However, we can make the following conclusions:
(i) the majority of branch IPMNs will remain stable,
some will grow or less commonly shrink on MRCP
follow-up; (ii) the larger branch IPMNs are more likely
to grow than smaller lesions; (iii) in asymptomatic
patients with BD-IPMN, a conservative management
with MRCP is an effective therapeutic choice in the
absence of clinical radiological parameters associated
with malignancy. A large cohort of patients with longer
follow-up should be considered to confirm these prelim-
inary results and to verify the safety of a conservative
management in these patients.
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